Akoya Biosciences (AKYA)
(Real Time Quote from BATS)
$2.77 USD
-0.11 (-3.82%)
Updated Sep 23, 2024 02:46 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
AKYA 2.77 -0.11(-3.82%)
Will AKYA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AKYA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AKYA
Akoya Biosciences (AKYA) Reports Q2 Loss, Misses Revenue Estimates
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
AKYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Other News for AKYA
Piper Sandler Sticks to Their Buy Rating for Akoya Biosciences (AKYA)
Akoya Biosciences price target lowered by $2 at Piper Sandler, here's why
Hold Rating on Akoya Biosciences Amidst Solid Operations and Market Headwinds
Akoya Biosciences just downgraded at Morgan Stanley, here's why
Akoya Biosciences price target lowered by 50c at Craig-Hallum, here's why